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beneﬁt, and with lack of personal experiences with TKR within
their social environment.
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In February 1998, the Food and Drug Administration (FDA)
released draft Guidance for Industry for the development 
of osteoarthritis (OA) products; providing recommendations
regarding the use of patient reported outcomes (PRO) in OA
product trials and labeling. OBJECTIVES: Identify trends in
PRO measurements in clinical trials and subsequent labeling
claims for drug products indicated for OA. METHODS: The
Physician Desk Reference (PDR) was searched for “Osteoarthri-
tis” within the indication. Summary Basis for Approvals (SBA)
for drug products indicated for the treatment of OA were
obtained from the FDA website (www.fda.gov). The FDA Draft
Guidance was reviewed for recommendations on the use of
PROs. Product labels and SBAs were evaluated chronologically
based on the date of approval and observed for trends in the use
of PROs before and after the release of the FDA guidance.
RESULTS: Overall, 11 products were identiﬁed as indicated for
OA, with 9 products speciﬁcally indicated for the relief of signs
and symptoms. Review of SBAs for the six products approved
prior to the introduction of the FDA guidance revealed that four
products measured patient global assessment, four included a
patient assessment, two incorporated a patient assessment of OA
activity, and one label contained a PRO claim. After the intro-
duction of the ﬁrst FDA draft guidance, ﬁve products were
approved and four included a patient global assessment, patient
assessment of pain, and the Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) in their pivotal trials,
coinciding with the Guidance’s recommendation for efﬁcacy end-
points in OA clinical trials. All four of these products contained
PRO information in their labels, including the WOMAC. CON-
CLUSIONS: Since the introduction of the FDA guidance for OA
products, there has been an increase in proportion of OA prod-
ucts that describe PRO measurement in clinical trials and PRO
claims appearing in OA labels.
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FACTOR-ALPHA INHIBITORS
Stockl K1, Jarrar M1,Tandon N2
1Prescription Solutions, Costa Mesa, CA, USA; 2Centocor, Inc,
Malvern, PA, USA
OBJECTIVES: To characterize dosing patterns and utilization of
tumor necrosis factor-alpha (TNF-alpha) inhibitors in rheuma-
toid arthritis (RA) patients as part of a quality assurance initia-
tive on appropriate use of TNF-alpha inhibitors. METHODS:
RA patients given inﬂiximab or etanercept between January
2001 and May 2002 were identiﬁed (N = 936) using pharmacy
and medical claims. Prescribers of the affected health plan were
requested via letter to send copies of identiﬁed patients’ charts.
TNF-alpha inhibitor utilization data were abstracted from avail-
able charts. Outcomes measured included TNF-alpha inhibitor
dosing, switching, and discontinuation. This retrospective study
started prior to the compliance date of the Health Insurance
Portability and Accountability Act (HIPAA); nevertheless, it was
conducted in a manner that was compliant with HIPAA require-
ments. RESULTS: Charts were obtained for 457 (49%) patients;
369 were eligible for study enrollment (164 [44%] received
inﬂiximab, 205 [56%] received etanercept). Mean ﬁrst doses
were 3.5mg/kg (inﬂiximab) and 27.9mg (etanercept). Subse-
quent doses were 4.2mg/kg (inﬂiximab) and 25.7mg (etaner-
cept). Overall, 67.2% of inﬂiximab infusions used no more than
the number of vials expected if dosed at 3mg/kg. The inﬂiximab
cohort had a signiﬁcantly lower switch rate than the etanercept
cohort (5.2% versus 15.5%, p = 0.006). Discontinuation (i.e.,
no documentation of TNF-alpha inhibitor during the 70-day
period prior to study end date or a chart order to discontinue
TNF-alpha inhibitor) occurred among 63.3% patients receiving
etanercept and 40.0% receiving inﬂiximab (p = 0.0002). 
CONCLUSIONS: Most patients received acceptable doses of
TNF-alpha inhibitor. A minority of patients receiving either med-
ication experienced an increase in dosing. Patients receiving
inﬂiximab had lower switch and discontinue rates than patients
receiving etanercept; further research is needed to examine
reasons for this observation. These results can be used by
managed care organizations to estimate pharmacy costs for
TNF-alpha inhibitors.
ARTHRITIS
ARTHRITIS—Health Policy Studies
PAR18
RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE
CYCLOOXYGENASE-2 INHIBITORS OVER OTHER
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A
MEDICAID MANAGED CARE POPULATION
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OBJECTIVES: To determine whether race inﬂuences a patient’s
likelihood of being prescribed selective cyclooxygenase-2
inhibitors (COX-2s) versus other nonsteroidal anti-inﬂammatory
agents (NSAIDs) in Medicaid managed care plans (MCOs).
METHODS: All medical and prescription claims for MCO
enrollees receiving at least one prescription for a COX-2 or
NSAID between January 2000 and June 2002 were retrieved.
Selected for study were adults claiming at least one COX-2 pre-
scription or NSAID prescription with a minimum 30 days supply
after June 2000; having 60 total days of supply or more over the
study period was also required for study inclusion. The proba-
bility of being a COX-2 user was estimated as a logistic function
of patient age, gender, race, city/suburban/rural residence, and
history of rheumatoid arthritis, osteoarthritis, chronic back pain,
acute pains, gastrointestinal problems, and comorbidities (hyper-
tension, hyperlipidemia, obesity, diabetes, renal problems,
alcohol/tobacco/drug abuse, cardiovascular events). RESULTS:
Sample COX-2 users numbered 4349 and NSAID users num-
bered 13,489. Half were African-American, three-quarters were
female, and a third was over 50 years old. After adjusting for
confounders, African-American and other races were a third less
likely to be COX-2 users than Caucasians (OR, 0.66; 95% CI,
0.61–0.72). Residence in Baltimore was an additional factor
reducing COX-2 usage (OR, 0.87; 95% CI, 0.80–0.95). Gender
was not a signiﬁcant factor. Age and all clinical covariates but
diabetes was signiﬁcant predictors at the 0.05 level. CONCLU-
SION: Race signiﬁcantly affected access to COX-2 medication
in Medicaid MCOs, even after adjusting for other demographic
and clinical variables. Cost to the patient was not a factor, as the
patient copayment was $1 for any prescription.
